ESR1 and breast carcinoma: Moreover the participation of a Cas/cSarc/pEGFR/pSTAT5b pathway in tamoxifen resistance ERα+ T47D breast cancer cells is reversed by dominant negative Y845F EGFR and C-terminal truncated STAT5b [9].